{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:16:00Z","timestamp":1782515760777,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with a DPYD genetic deficiency who receive capecitabine are at increased risk of severe, potentially fatal toxicities due to impaired drug metabolism. Genetic testing for this deficiency allows for proactive dose adjustments to mitigate these risks. We evaluated the cost-effectiveness of DPYD genotyping prior to capecitabine administration, followed by dose modification for patients with metastatic breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a state-transition model to simulate health outcomes and costs for a cohort of 62-year-old women with metastatic breast cancer from the perspective of the U.S. healthcare payer. Costs and utilities were derived from the literature to calculate quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) for DPYD genotyping compared to no DPYD genotyping. We conducted deterministic and probabilistic sensitivity analyses to identify factors influencing cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The genotyping strategy was cost-effective, with a cost of $2,832 yielding 1.16 QALYs, compared to $2,677 and 1.15 QALYs for the no-genotyping strategy. This resulted in an ICER of $12,916\/QALY and $10,333 per life-year-gained. In probabilistic sensitivity analysis, the genotyping strategy was cost-effective in 99% of the simulations, using a willingness-to-pay threshold of $100,000\/QALY. Results from scenario analyses testing key assumptions also showed that genotyping is cost-effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings support the implementation of DPYD genotyping prior to capecitabine initiation in metastatic breast cancer patients. This strategy exemplifies the value of personalized medicine and pharmacogenomics in improving treatment safety and effectiveness. As sequencing technologies advance and become affordable, integration of genotyping into routine oncology care is increasingly feasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07948-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:45:33Z","timestamp":1774683933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer"],"prefix":"10.1007","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2865-9147","authenticated-orcid":false,"given":"Tanvi","family":"Chiddarwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Blaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"7948_CR1","unstructured":"Cancer of the Breast (Female)-Cancer Stat Facts (2024) SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed 2 Mar 2024"},{"issue":"2","key":"7948_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/00003495-200363020-00009","volume":"63","author":"AJ Wagstaff","year":"2003","unstructured":"Wagstaff AJ, Ibbotson T, Goa KL (2003) Capecitabine. Drugs 63(2):217\u2013236. https:\/\/doi.org\/10.2165\/00003495-200363020-00009","journal-title":"Drugs"},{"issue":"7","key":"7948_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"ABP van Kuilenburg","year":"2004","unstructured":"van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939\u2013950. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004","journal-title":"Eur J Cancer"},{"key":"7948_CR4","unstructured":"Dean L, Kane M (2024) Capecitabine therapy and DPYD genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries. National Center for Biotechnology Information (US); 2012. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK385155\/. Accessed 9 Dec 2024"},{"issue":"5","key":"7948_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11050199","volume":"11","author":"TJ Wigle","year":"2019","unstructured":"Wigle TJ, Tsvetkova EV, Welch SA, Kim RB (2019) DPYD and fluorouracil-based chemotherapy: mini review and case report. Pharmaceutics 11(5):199. https:\/\/doi.org\/10.3390\/pharmaceutics11050199","journal-title":"Pharmaceutics"},{"issue":"1","key":"7948_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12981-5","volume":"24","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, de Almeida Barbosa AB, Sano VKT, Kelly FA, Burbano RMR (2024) Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis. BMC Cancer 24(1):1210. https:\/\/doi.org\/10.1186\/s12885-024-12981-5","journal-title":"BMC Cancer"},{"issue":"12","key":"7948_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26(12):1008\u20131016. https:\/\/doi.org\/10.1002\/onco.13967","journal-title":"Oncologist"},{"issue":"2","key":"7948_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-019-05144-9","volume":"175","author":"C Stavraka","year":"2019","unstructured":"Stavraka C, Pouptsis A, Okonta L et al (2019) Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. Breast Cancer Res Treat 175(2):511\u2013517. https:\/\/doi.org\/10.1007\/s10549-019-05144-9","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"7948_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49441","volume":"7","author":"R Roncato","year":"2024","unstructured":"Roncato R, Bignucolo A, Peruzzi E et al (2024) Clinical benefits and utility of pretherapeutic DPYD and UGT1A1 testing in gastrointestinal cancer: a secondary analysis of the PREPARE randomized clinical trial. JAMA Netw Open 7(12):e2449441. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.49441","journal-title":"JAMA Netw Open"},{"issue":"35","key":"7948_CR10","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1200\/JCO.22.02780","volume":"41","author":"JE Knikman","year":"2023","unstructured":"Knikman JE, Wilting TA, Lopez-Yurda M et al (2023) Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy-a matched-pair analysis. J Clin Oncol 41(35):5411\u20135421. https:\/\/doi.org\/10.1200\/JCO.22.02780","journal-title":"J Clin Oncol"},{"issue":"3","key":"7948_CR11","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/j.clcc.2022.05.001","volume":"21","author":"GA Brooks","year":"2022","unstructured":"Brooks GA, Tapp S, Daly AT, Busam JA, Tosteson ANA (2022) Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer. Clin Colorectal Cancer 21(3):e189\u2013e195. https:\/\/doi.org\/10.1016\/j.clcc.2022.05.001","journal-title":"Clin Colorectal Cancer"},{"key":"7948_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.vhri.2023.04.004","volume":"37","author":"SA Fariman","year":"2023","unstructured":"Fariman SA, Jahangard Rafsanjani Z, Hasanzad M, Niksalehi K, Nikfar S (2023) Upfront DPYD genotype-guided treatment for fluoropyrimidine-based chemotherapy in advanced and metastatic colorectal cancer: a cost-effectiveness analysis. Value Health Reg Issues 37:71\u201380. https:\/\/doi.org\/10.1016\/j.vhri.2023.04.004","journal-title":"Value Health Reg Issues"},{"key":"7948_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1200\/JCO.2020.38.4_suppl.168","volume":"38","author":"Z Rivers","year":"2020","unstructured":"Rivers Z, Stenehjem DD, Jacobson P, Lou E, Nelson A, Kuntz KM (2020) A cost-effectiveness analysis of pretreatment DPYD and UGT1A1 screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI+bevacizumab (FOLFIRI+Bev). JCO 38:168\u2013168. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.168","journal-title":"JCO"},{"issue":"2","key":"7948_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"7948_CR15","unstructured":"EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine (2024) European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine. Accessed 2 March 2024"},{"key":"7948_CR16","unstructured":"Research C for DE and. Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. FDA. Published online February 10, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine. Accessed 6 Mar 2026"},{"key":"7948_CR17","doi-asserted-by":"publisher","unstructured":"ASCO clinical notice: reaffirming the necessity for DPYD genotyping in fluoropyrimidine therapy (2026) ASCO Connection. https:\/\/connection.asco.org\/do\/https:\/\/doi.org\/10.1200\/acon.26.000011\/full\/. Accessed 6 Mar 2026","DOI":"10.1200\/acon.26.000011\/full"},{"key":"7948_CR18","unstructured":"Breast cancer statistics (2026) How Common Is Breast Cancer? https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html. Accessed 20 Jan 2026"},{"issue":"10","key":"7948_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316(10):1093\u20131103. https:\/\/doi.org\/10.1001\/jama.2016.12195","journal-title":"JAMA"},{"issue":"9","key":"7948_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC (2014) Updating cost-effectiveness\u2013the curious resilience of the <span>$<\/span>50,000-per-QALY threshold. N Engl J Med 371(9):796\u2013797. https:\/\/doi.org\/10.1056\/NEJMp1405158","journal-title":"N Engl J Med"},{"issue":"1","key":"7948_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F et al (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med 20(1):23. https:\/\/doi.org\/10.1186\/s12916-021-02204-0","journal-title":"BMC Med"},{"issue":"1","key":"7948_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12885-018-4380-z","volume":"18","author":"S Munker","year":"2018","unstructured":"Munker S, Gerken M, Fest P et al (2018) Chemotherapy for metastatic colon cancer: no effect on survival when the dose is reduced due to side effects. BMC Cancer 18(1):455. https:\/\/doi.org\/10.1186\/s12885-018-4380-z","journal-title":"BMC Cancer"},{"key":"7948_CR23","unstructured":"Common terminology criteria for adverse events (CTCAE). Published online 2017"},{"issue":"12","key":"7948_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/OP.20.00553","volume":"16","author":"F Innocenti","year":"2020","unstructured":"Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz HJ, Milano G (2020) All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide. JCO Oncol Pract 16(12):793\u2013798. https:\/\/doi.org\/10.1200\/OP.20.00553","journal-title":"JCO Oncol Pract"},{"issue":"34","key":"7948_CR25","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","volume":"29","author":"MR Stockler","year":"2011","unstructured":"Stockler MR, Harvey VJ, Francis PA et al (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. JCO 29(34):4498\u20134504. https:\/\/doi.org\/10.1200\/JCO.2010.33.9101","journal-title":"JCO"},{"key":"7948_CR26","unstructured":"Arias E. United States Life Tables, 202"},{"issue":"11","key":"7948_CR27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM et al (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19(11):1459\u20131467. https:\/\/doi.org\/10.1016\/S1470-2045(18)30686-7","journal-title":"Lancet Oncol"},{"key":"7948_CR28","unstructured":"CLFS Files | CMS. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs\/files. Accessed 2 Mar 2024"},{"key":"7948_CR29","unstructured":"ASP Pricing Files | CMS. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files. Accessed 9 Dec 2024"},{"key":"7948_CR30","unstructured":"020896s044s045s046s047s048s049s050s051lbl.pdf. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020896s044s045s046s047s048s049s050s051lbl.pdf. Accessed 9 Dec 2024"},{"issue":"16","key":"7948_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/jnci\/djj305","volume":"98","author":"MJ Hassett","year":"2006","unstructured":"Hassett MJ, O\u2019Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. JNCI J Natl Cancer Inst 98(16):1108\u20131117. https:\/\/doi.org\/10.1093\/jnci\/djj305","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"7948_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J (2006) Health state utilities for metastatic breast cancer. Br J Cancer 95(6):683\u2013690. https:\/\/doi.org\/10.1038\/sj.bjc.6603326","journal-title":"Br J Cancer"},{"issue":"5","key":"7948_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.bjc.6604501","volume":"99","author":"B Sherrill","year":"2008","unstructured":"Sherrill B, Amonkar MM, Stein S, Walker M, Geyer C, Cameron D (2008) Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 99(5):711\u2013715. https:\/\/doi.org\/10.1038\/sj.bjc.6604501","journal-title":"Br J Cancer"},{"issue":"4","key":"7948_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2217\/pme-2022-0133","volume":"20","author":"R Koleva-Kolarova","year":"2023","unstructured":"Koleva-Kolarova R, Vellekoop H, Huygens S et al (2023) Budget impact and transferability of cost\u2013effectiveness of DPYD testing in metastatic breast cancer in three health systems. Personalized Med 20(4):357\u2013374. https:\/\/doi.org\/10.2217\/pme-2022-0133","journal-title":"Personalized Med"},{"issue":"18","key":"7948_CR35","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB (2006) Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with caucasians. Clin Cancer Res 12(18):5491\u20135495. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0747","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7948_CR36","doi-asserted-by":"publisher","first-page":"e958","DOI":"10.1200\/OP.21.00874","volume":"18","author":"K Koo","year":"2022","unstructured":"Koo K, Pasternak AL, Henry NL, Sahai V, Hertz DL (2022) Survey of US medical oncologists\u2019 practices and beliefs regarding DPYD testing before fluoropyrimidine chemotherapy. JCO Oncol Pract 18(6):e958\u2013e965. https:\/\/doi.org\/10.1200\/OP.21.00874","journal-title":"JCO Oncol Pract"},{"key":"7948_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1184895","volume":"14","author":"Q Xiao","year":"2023","unstructured":"Xiao Q, Zhang W, Jing J et al (2023) Patterns of de novo metastasis and survival outcomes by age in breast cancer patients: a SEER population-based study. Front Endocrinol (Lausanne) 14:1184895. https:\/\/doi.org\/10.3389\/fendo.2023.1184895","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07948-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07948-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07948-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:36:18Z","timestamp":1777880178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07948-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7948"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07948-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7992444\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2"}}